STRUCTURE THERAPEUTICS INC. AMERICAN DEPOSITARY SHARES
NASDAQ: GPCR (Structure Therapeutics Inc.)
Kemas kini terakhir: 18 jam lalu16.13
-0.99 (-5.78%)
| Penutupan Terdahulu | 17.12 |
| Jumlah Dagangan | 786,235 |
| Purata Dagangan (3B) | 1,176,959 |
| Modal Pasaran | 1,154,752,256 |
| Harga / Buku (P/B) | 1.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2026 |
| EPS Cair (TTM) | -3.90 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.56% |
| Nisbah Semasa (MRQ) | 11.90 |
| Aliran Tunai Operasi (OCF TTM) | -271.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -148.98 M |
| Pulangan Atas Aset (ROA TTM) | -20.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.51% |
Sentimen Berita
-
Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
12 Nov, 6:00AM
-
Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
6 hari lalu, 5:20PM
AISkor Stockmoo
| Nilai 30% | -0.7 |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -3.8 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga telah jatuh jauh di bawah purata itu. Dagangan lebih tinggi pada hari harga turun. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | -0.1 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini bercampur atau neutral. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 3.3 |
| Institusi bersih +5.81% daripada saham dalam pemfailan 13F terkini: 78 pemegang menambah, 112 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +1.2% dari 31 Aug hingga 30 Oct 2026, 6.5 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak tidak sependapat, jadi skor dilemahkan. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham kebanyakannya menurun. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -0.72 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Structure Therapeutics Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| GPCR | 1 B | - | - | 1.01 | -0.7 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
|
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.10% |
| % Dimiliki oleh Institusi | 97.79% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2026 | 6,555,555 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 34.48%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 78 | 16,027,429 |
| Berkurang | 112 | 9,944,170 |
| Baharu | 28 | 8,724,695 |
| Dijual habis | 46 | 2,322,694 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 5,927,622 | 6.5 |
| 15 Oct 2026 | 7,147,328 | 4.8 |
| 30 Sep 2026 | 7,540,480 | 5.2 |
| 15 Sep 2026 | 6,605,011 | 5.2 |
| 31 Aug 2026 | 5,854,907 | 7.9 |
| 14 Aug 2026 | 6,079,970 | 10.4 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?
Structure Therapeutics (GPCR) put its third quarter in focus for investors after reporting a wider net loss of US$144.76 million and a higher loss per share, with year-to-date figures showing a similar pattern. Structure Therapeutics’ share price has fallen sharply over 2026, with a year to date… |
| 13 Nov 2026 | Yahoo Finance |
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead. |
| 12 Nov 2026 | Yahoo Finance |
Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
Retrospective analysis at ObesityWeek® will explore how AI-based modeling can provide context for longer-term obesity study resultsSAN FRANCISCO, CA / ACCESS Newswire / November 12, 2026 / Unlearn today announced a collaboration with Structure Therapeutics Inc., a clinical-stage biopharmaceutical… |
| 09 Nov 2026 | Yahoo Finance |
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies… |
| 04 Nov 2026 | Yahoo Finance |
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will… |
| 27 Oct 2026 | Yahoo Finance |
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges. |
| 21 Oct 2026 | Yahoo Finance |
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth. |
| 19 Oct 2026 | Yahoo Finance |
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming… |
| 19 Oct 2026 | Yahoo Finance |
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results. |
| 16 Oct 2026 | Yahoo Finance |
Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
Structure Therapeutics has seen a sharp reset in market sentiment this year, which puts fresh focus on whether the current share price lines up with what its balance sheet can support. With the stock under pressure, the central question is how that drop squares with its book value. Year to date… |
| 12 Oct 2026 | Yahoo Finance |
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential. |
| 08 Oct 2026 | Yahoo Finance |
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
LLY's recent dip reflects valuation and competition concerns, but strong GLP-1 demand, pipeline growth and diversification support its long-term outlook. |
| 30 Sep 2026 | Yahoo Finance |
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches. |
| 23 Sep 2026 | Yahoo Finance |
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1… |
| 22 Sep 2026 | Yahoo Finance |
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger. |
| 22 Sep 2026 | Yahoo Finance |
Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share… |
| 22 Sep 2026 | Yahoo Finance |
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions. |
| Papar semua | ||
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |